← Back

Wire · opportunities

Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology ...

Published

25 August 2026

Topic

opportunities

Sectors

Medtech

Geography

United States

Source

Read at abbott.mediaroom.com

Verified

Fusion42 · 26 August 2026 · Fusion42 review

Abbott received FDA authorization for Libre Duo 10 Day, the first dual glucose-ketone sensing wearable that provides real-time glucose monitoring and alerts for rising ketones to prevent diabetic ketoacidosis (DKA). The device integrates with the latest Libre app and is compatible with leading automated insulin delivery systems, aiming to reduce serious DKA risks.

This Wire brief sits within Fusion42's coverage of Medtech, and 4 sources have reported it between 25 Aug 2026 and 26 Aug 2026.

◆ The Wire takeaway

Diabetes device makers just gained permission to combine glucose and ketone monitoring into a single wearable. If you build diabetes hardware or software, start integrating ketone sensing or partner with Abbott to stay competitive.

Coverage

4 sources · first reported 25 Aug 2026 · latest 26 Aug 2026

Related on Wire

Topics

Medtechdiabetes-careFDA-approvalbiowearableketone-monitoringglucose-monitoring